Ingredient supplier AIDP announced that Puremune, its branded insoluble yeast beta-glucan from Immudyne Nutritional, has secured a product license from Health Canada indicating it as a source of yeast beta glucan with immune-modulating properties at a dose of 30 mg.
 
Puremune is sourced solely from the U.S. and manufactured at a U.S. Food and Drug Administration (FDA) registered facility. Puremune has a unique structure, which positively affects its immune-modulating properties, according to AIDP, and its low dose allows for easy combination with other immune support ingredients. In comparison, other baker’s yeast beta-glucans are typically dosed between 250 and 500 mg in adults, around ten times the dose that is used for Puremune.
 
Health Canada’s claims authorizations are often relied upon by other countries due to the due diligence that takes place for the approval of a Health Canada claim, according to AIDP.
 
Additionally, with GRAS (Generally Recognized as Safe) status, the ingredient can be used in a wide variety of product formats, and the low dose allows for formulation flexibility. Organic forms are also available upon request.
 
“Securing a product license from Health Canada requires an extensive amount of preparation,” Mark Thurston, AIDP president, said. “Given the expansion of the immune segment and the uniqueness of Puremune, we are confident our customers can leverage this new Health Canada Claim.”
 
“We are very pleased with the Health Canada development,” said Mark McLaughlin, CEO of the Puremune manufacturer Immudyne Nutritional. “Moreover, out ream anticipates that in the very near future, we will be able to show new, impactful scientific data to further strengthen Puremune’s position.”